NDAOPHTHALMICSUSPENSION/DROPS
Approved
Jun 1963
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
4/8 — Partial
MAXITROL (neomycin sulfate, polymyxin b sulfate and dexamethasone) by Novartis is corticosteroid hormone receptor agonists [moa]. Approved for corticosteroid [epc]. First approved in 1963.
Drug data last refreshed 6d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MAXITROL is a fixed-dose ophthalmic suspension combining neomycin sulfate and polymyxin B sulfate (broad-spectrum antibiotics) with dexamethasone (corticosteroid). It treats bacterial eye infections and associated inflammation by inhibiting bacterial protein synthesis and suppressing local immune response. The product has been a cornerstone of antibiotic-steroid combination therapy in ophthalmology since 1963.
LOE Approaching
Declining
With minimal annual spending ($3K) and approaching loss of exclusivity, the MAXITROL brand team is likely small and focused on defending legacy market share against generic and branded alternatives rather than growth initiatives.
Mechanism of Action
Corticosteroid Hormone Receptor Agonists
Pharmacologic Class:
Corticosteroid
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
MAXITROL presents a defensive, legacy-product career opportunity with minimal growth potential and zero linked job openings, reflecting its approaching loss of exclusivity and negligible commercial footprint ($3K annual spending). Roles on this product are primarily cost-containment, compliance, and managed market decline rather than commercial expansion or clinical innovation.
Brand Manager
Worked on MAXITROL at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.